<DOC>
	<DOCNO>NCT00005791</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy treat patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose weekly irinotecan combination weekly fluorouracil cisplatin patient locally advance metastatic solid tumor . II . Determine dose limit toxicity combination regimen patient population . III . Establish recommend phase II dose combination regimen patient . IV . Evaluate safety tolerability regimen patient . V. Observe responses combination chemotherapy patient . VI . Measure pretreatment biopsy level expression thymidylate synthase , topoisomerase I , ERCC-1 , thymidine phosphorylase , dihydropyrimidine dehydrogenase correlate response resistance combination chemotherapy patient . OUTLINE : This dose escalation study irinotecan fluorouracil . Patients receive cisplatin IV 30 minute follow fluorouracil IV several minute follow irinotecan IV 30 minute day 1 , 8 , 15 , 22 . Treatment continue every 6 week absence unacceptable toxicity disease progression minimum 3 course . Cohorts 3-6 patient receive escalate dos irinotecan fluorouracil maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow 30 day death . PROJECTED ACCRUAL : A total 3-36 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor malignancy amenable curative surgery chemoradiation No CNS metastases , carcinomatous meningitis , interstitial pulmonary fibrosis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST great 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis ) No know Gilbert 's disease Renal : Creatinine great 1.5 mg/dL Calcium le 12.0 mg/dL No symptomatic hypercalcemia Cardiovascular : No unstable angina No New York Heart Association class III IV cardiac disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active uncontrolled infection No history seizure disorder No uncontrolled diabetes mellitus , define random blood sugar 250 mg/dL great PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 1 prior chemotherapy regimen Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No prior mantle irradiation , hemibody irradiation , radiation pelvis lumbar spine Surgery : See Disease Characteristics Other : No concurrent phenytoin , phenobarbital , antiepileptic medication No concurrent prochlorperazine day irinotecan administration No concurrent prophylactic loperamide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>